Biological markers increase clinical trial success rate of new breast cancer drugs

October 1, 2012

Using biological markers—genetic characteristics that are associated with some patients with breast cancer—can increase the success rate of clinical trials for breast cancer drugs by almost 50 per cent, says new research from the University of Toronto Mississauga.

"It's been increasingly difficult for pharmaceutical companies to bring new drugs to market," says Jayson Parker, a faculty member in the Department of Biology and analyst at the University of Toronto. "On average, about 80 per cent of drugs fail at some point in the clinical trial process."

There are currently no clear estimates of success rates in clinical trials for breast cancer drugs and the factors that can impact success. The research team examined clinical trial drug development programs from 1998 to 2012 to determine how often breast cancer drugs were brought to market. The study examined advanced and as well as patients that have been exposed to the taxane and anthracycline.

"We found that only 14 per cent of drugs that undergo human testing for advanced and metastatic breast cancer are eventually approved," says Parker. "This is worse than the average for the industry as a whole."

According to Parker, some researchers have hypothesized that in the era of personalized medicine, , or biomarkers, could be used to improve clinical trial success rates and help bring more drugs to market faster. To test this hypothesis, Parker and his team examined the clinical trial success rates for drugs tested on who have a particular biomarker (HER2). Biomarkers form part of the pathway involved in cancer cell development and can influence how a patient responds to therapy.

When the team compared clinical trials that targeted patients with the HER2 biomarker to those that did not, they found the success rate of drug development increased from 15 per cent to 23 per cent.

Improving the success rate of clinical trials also has an economic impact. Parker's team found that using the HER2 biomarker in the design of clinical trials resulted in a cost savings of 27 per cent. "This can means millions of dollars in cost reduction for a clinical trial," says Parker.

Although this finding may be limited to the HER2 biomarker in breast cancer, Parker says the results are encouraging. "This is the first study that has made a systematic comparison between patients with and without a biomarker," he says. "It provides us with concrete initial evidence that the use of a biomarker can help improve clinical trial success rates in breast cancer. We are now exploring whether this finding holds true for other biomarkers in other cancers."

The paper was published in the journal of Research and Treatment.

Explore further: Metastatic breast cancer: Bevacizumab slows progression, but has no impact on survival

Related Stories

Metastatic breast cancer: Bevacizumab slows progression, but has no impact on survival

July 10, 2012
The cancer drug bevacizumab (Avastin) offers only a modest benefit in delaying disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane researchers. The researchers assessed ...

New therapy for HER2-positive breast cancer developed

July 26, 2011
Patients with HER2-positive breast cancer may soon have an alternative therapy when they develop resistance to trastuzumab, also known as Herceptin, according to a laboratory finding published in Clinical Cancer Research.

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.